121 related articles for article (PubMed ID: 17434826)
1. Comparison of tablet and disk diffusion methods for fluconazole and voriconazole in vitro activity testing against clinical yeast isolates.
Rementeria A; Sanchez-Vargas LO; Villar M; Casals JB; Carrillo-Munoz AJ; Rodriguez Andres C; Eraso E; Quindos G
J Chemother; 2007 Apr; 19(2):172-7. PubMed ID: 17434826
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Neo-Sensitabs tablet diffusion assay results on three different agar media with CLSI broth microdilution M27-A2 and disk diffusion M44-A results for testing susceptibilities of Candida spp. and Cryptococcus neoformans to amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole.
Espinel-Ingroff A; Canton E; Gibbs D; Wang A
J Clin Microbiol; 2007 Mar; 45(3):858-64. PubMed ID: 17215342
[TBL] [Abstract][Full Text] [Related]
3. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
Lee SC; Lo HJ; Fung CP; Lee N; See LC
J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
[TBL] [Abstract][Full Text] [Related]
4. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Rinaldi MG; Barnes R; Hu B; Veselov AV; Tiraboschi N; Nagy E; Gibbs DL
J Clin Microbiol; 2005 Dec; 43(12):5848-59. PubMed ID: 16333066
[TBL] [Abstract][Full Text] [Related]
5. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
6. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets.
Carrillo-Muñoz AJ; Quindós G; del Valle O; Santos P; Giusiano G; Ezkurra PA; Estivill MD; Casals JB
Chemotherapy; 2008; 54(1):38-42. PubMed ID: 18073469
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the VITEK 2 system (AST-YSO1 cards) for antifungal susceptibility testing against different Candida species].
Ochiuzzi ME; Arechavala A; Guelfand L; Maldonado I; Soloaga R;
Rev Argent Microbiol; 2014; 46(2):111-8. PubMed ID: 25011594
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of fluconazole and voriconazole against clinical isolates of Candida spp. determined by disk diffusion testing in Turin, Italy.
Mandras N; Tullio V; Allizond V; Scalas D; Banche G; Roana J; Robbiano F; Fucale G; Malabaila A; Cuffini AM; Carlone N
Antimicrob Agents Chemother; 2009 Apr; 53(4):1657-9. PubMed ID: 19188375
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
[TBL] [Abstract][Full Text] [Related]
10. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.
Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ;
Diagn Microbiol Infect Dis; 2009 Sep; 65(1):27-34. PubMed ID: 19679232
[TBL] [Abstract][Full Text] [Related]
11. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
J Clin Microbiol; 2007 Jan; 45(1):70-5. PubMed ID: 17079501
[TBL] [Abstract][Full Text] [Related]
12. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.
Buchta V; Vejsova M; Vale-Silva LA
Folia Microbiol (Praha); 2008; 53(2):153-60. PubMed ID: 18837162
[TBL] [Abstract][Full Text] [Related]
13. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole.
Matar MJ; Ostrosky-Zeichner L; Paetznick VL; Rodriguez JR; Chen E; Rex JH
Antimicrob Agents Chemother; 2003 May; 47(5):1647-51. PubMed ID: 12709335
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility of Candida species using the Clinical and Laboratory Standards Institute disk diffusion and broth microdilution methods.
Noake T; Kuriyama T; White PL; Potts AJ; Lewis MA; Williams DW; Barnes RA
J Chemother; 2007 Jun; 19(3):283-7. PubMed ID: 17594923
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay.
Azevedo AC; Bizerra FC; da Matta DA; de Almeida LP; Rosas R; Colombo AL
Mycopathologia; 2011 Jun; 171(6):411-6. PubMed ID: 21181497
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion.
Hazen KC; Baron EJ; Colombo AL; Girmenia C; Sanchez-Sousa A; del Palacio A; de Bedout C; Gibbs DL;
J Clin Microbiol; 2003 Dec; 41(12):5623-32. PubMed ID: 14662952
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of microdilution and disk diffusion methods for the detection of fluconazole and voriconazole susceptibility against clinical Candida glabrata isolates and determination of changing susceptibility with new CLSI breakpoints].
Hazırolan G; Sarıbaş Z; Arıkan Akdağlı S
Mikrobiyol Bul; 2016 Jul; 50(3):428-37. PubMed ID: 27525398
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of voriconazole against Mexican oral yeast isolates.
Sánchez Vargas LO; Eraso E; Carrillo-Muñoz AJ; Aguirre JM; Gaitán-Cepeda LA; Quindós G
Mycoses; 2010 May; 53(3):200-3. PubMed ID: 19389066
[TBL] [Abstract][Full Text] [Related]
19. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Bijie H; Dzierzanowska D; Klimko NN; Letscher-Bru V; Lisalova M; Muehlethaler K; Rennison C; Zaidi M;
J Clin Microbiol; 2009 Jan; 47(1):117-23. PubMed ID: 19005141
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of voriconazole against Candida species isolated in Taiwan.
Yang YL; Cheng HH; Lo HJ
Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
